{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:35:08Z","timestamp":1794648908419,"version":"4.9.1"},"reference-count":408,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1059660"],"award-info":[{"award-number":["1059660"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1156072"],"award-info":[{"award-number":["1156072"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cyto.2021.155593","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T22:57:24Z","timestamp":1621983444000},"page":"155593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?"],"prefix":"10.1016","volume":"144","author":[{"given":"Gerwyn","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-6363","authenticated-orcid":false,"given":"Chiara C.","family":"Bortolasci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6101-0139","authenticated-orcid":false,"given":"Basant K.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Athan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Walder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2021.155593_b0005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1164\/rccm.202007-2934ED","article-title":"Rewiring the immune response in COVID-19","volume":"202","author":"Chalmers","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b0010","doi-asserted-by":"crossref","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cyto.2021.155593_b0015","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","author":"Liu","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cyto.2021.155593_b0020","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.cyto.2021.155593_b0025","first-page":"eabb8925","article-title":"Cytokine release syndrome in severe COVID-19","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cyto.2021.155593_b0030","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018Cytokine Storm' in COVID-19","author":"Ye","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.cyto.2021.155593_b0040","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cyto.2021.155593_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.cyto.2021.155593_b0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/acr2.11135","article-title":"Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome","volume":"2","author":"Monteagudo","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.cyto.2021.155593_b0060","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.cyto.2021.155593_b0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pbj.2017.05.005","article-title":"Role of platelets in immune system and inflammation","volume":"2","author":"Sonmez","year":"2017","journal-title":"Porto Biomed. J."},{"key":"10.1016\/j.cyto.2021.155593_b0070","article-title":"The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing","author":"Liao","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","author":"Shi","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cyto.2021.155593_b0080","article-title":"Aveolar macrophage activation and cytokine storm in the pathogenesis of severe COVID-19","author":"Wang","year":"2020","journal-title":"Res. Square"},{"key":"10.1016\/j.cyto.2021.155593_b0085","doi-asserted-by":"crossref","first-page":"117583","DOI":"10.1016\/j.lfs.2020.117583","article-title":"COVID-19: melatonin as a potential adjuvant treatment","volume":"250","author":"Zhang","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2021.155593_b0090","article-title":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients","author":"Chen","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b0095","doi-asserted-by":"crossref","first-page":"198171","DOI":"10.1016\/j.virusres.2020.198171","article-title":"IFN-\u03b3 is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection","volume":"289","author":"Gadotti","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.cyto.2021.155593_b0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","article-title":"Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison","volume":"22","author":"Galani","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585647","article-title":"Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0110","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","author":"Diao","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b0115","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.cyto.2021.155593_b0120","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.cyto.2021.155593_b0125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-0304-7","article-title":"Fighting COVID-19 exhausts T cells","volume":"20","author":"Moon","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0130","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0140","article-title":"The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients","volume":"106504","author":"Yang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2021.155593_b0145","article-title":"Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19","author":"Liu","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.cyto.2021.155593_b0150","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06033-2","article-title":"COVID-19 pneumonia: different respiratory treatments for different phenotypes?","author":"Gattinoni","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b0155","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202003-0817LE","article-title":"Covid-19 does not lead to a \u201ctypical\u201d acute respiratory distress syndrome","author":"Gattinoni","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b0160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12640-019-00054-6","article-title":"Breakdown of the paracellular tight and adherens junctions in the gut and blood brain barrier and damage to the vascular barrier in patients with deficit schizophrenia","volume":"36","author":"Maes","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.cyto.2021.155593_b0165","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14854","article-title":"The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome","author":"Ranucci","year":"2020","journal-title":"J. Thrombosis Haemostasis: JTH."},{"key":"10.1016\/j.cyto.2021.155593_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2020.03.032","article-title":"Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1","author":"Tang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.cyto.2021.155593_b0175","doi-asserted-by":"crossref","DOI":"10.1002\/art.41285","article-title":"On the alert for cytokine storm: immunopathology in COVID-19","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"key":"10.1016\/j.cyto.2021.155593_b0180","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxx031","article-title":"Hyperferritinemia and inflammation","volume":"29","author":"Kernan","year":"2017","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0185","doi-asserted-by":"crossref","first-page":"118166","DOI":"10.1016\/j.lfs.2020.118166","article-title":"The pathophysiology of SARS-CoV-2: a suggested model and therapeutic approach","volume":"258","author":"Morris","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2021.155593_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118114","article-title":"Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: role of lncRNAs in cytokine storm modulation","volume":"257","author":"Paniri","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2021.155593_b0195","article-title":"The SARS-CoV-2 spike protein primes inflammasome-mediated interleukin-1- beta secretion in COVID-19 patient-derived macrophages","author":"Theobald","year":"2020","journal-title":"Res. Square"},{"key":"10.1016\/j.cyto.2021.155593_b0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00011-020-01413-2","article-title":"Inflammasome formation in the lungs of patients with fatal COVID-19","volume":"70","author":"Toldo","year":"2021","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.cyto.2021.155593_b0205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0317-2","article-title":"Macrophages: a Trojan horse in COVID-19?","author":"Park","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0215","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.23812\/20-1-E","article-title":"Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy","volume":"34","author":"Conti","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.cyto.2021.155593_b0220","doi-asserted-by":"crossref","unstructured":"G. Magro, SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the \u2018culprit lesion\u2019 of ARDS onset? What is there besides Tocilizumab? SGP130Fc, Cytokine: X. 2 (2020) 10029..","DOI":"10.1016\/j.cytox.2020.100029"},{"key":"10.1016\/j.cyto.2021.155593_b0225","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s13054-020-03166-0","article-title":"Blocking IL-1 to prevent respiratory failure in COVID-19","volume":"24","author":"van de Veerdonk","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.cyto.2021.155593_b0230","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139834","article-title":"Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease","volume":"5","author":"Zhao","year":"2020","journal-title":"JCI Insight."},{"key":"10.1016\/j.cyto.2021.155593_b0235","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41577-020-00467-x","article-title":"IL-18-dependent MAIT cell activation in COVID-19","volume":"20","author":"Gea-Mallorqu\u00ed","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0240","doi-asserted-by":"crossref","first-page":"155302","DOI":"10.1016\/j.cyto.2020.155302","article-title":"Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19","volume":"137","author":"Sat\u0131\u015f","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2021.155593_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine storm in COVID-19: the current evidence and treatment strategies","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0250","article-title":"Pulmonary and cardiac pathology in covid-19: the first autopsy series from New Orleans","author":"Fox","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b0255","article-title":"Pathogenesis of COVID-19 from a cell biologic perspective","volume":"2000607","author":"Mason","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cyto.2021.155593_b0260","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","article-title":"Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer","volume":"15","author":"Tian","year":"2020","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.cyto.2021.155593_b0265","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.cyto.2021.155593_b0270","article-title":"Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection","author":"Yang","year":"2020","journal-title":"SSRN Electronic J."},{"key":"10.1016\/j.cyto.2021.155593_b0275","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-020-0318-5","article-title":"Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient","author":"Yao","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.cyto.2021.155593_b0280","first-page":"E009","article-title":"A pathological report of three COVID-19 cases by minimally invasive autopsies","volume":"49","author":"Yao","year":"2020","journal-title":"Zhonghua Bing Li Xue Za Zhi."},{"key":"10.1016\/j.cyto.2021.155593_b0285","article-title":"Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing","author":"Wen","year":"2020","journal-title":"MedRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b0290","article-title":"COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome","author":"Zhang","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.560381","article-title":"Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology","volume":"11","author":"G\u00f3mez-Rial","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41420-020-0255-6","article-title":"The role of neutrophil death in chronic inflammation and cancer","volume":"6","author":"Brostjan","year":"2020","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.cyto.2021.155593_b0305","doi-asserted-by":"crossref","first-page":"16628","DOI":"10.1038\/s41598-017-16778-4","article-title":"Mineral particles stimulate innate immunity through neutrophil extracellular traps containing HMGB1","volume":"7","author":"Peng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b0310","article-title":"The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients","volume":"1\u201310","author":"Hariharan","year":"2020","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cyto.2021.155593_b0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","article-title":"How COVID-19 induces cytokine storm with high mortality","volume":"40","author":"Hojyo","year":"2020","journal-title":"Inflamm Regen."},{"key":"10.1016\/j.cyto.2021.155593_b0320","article-title":"NF-\u03baB signalling as a pharmacological target in COVID-19: potential roles for IKK\u03b2 inhibitors","volume":"1\u20137","author":"Kandasamy","year":"2021","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.cyto.2021.155593_b0325","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","author":"Ackermann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0330","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/jth.14781","article-title":"Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia","volume":"18","author":"Lillicrap","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cyto.2021.155593_b0335","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.cyto.2021.155593_b0340","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12959-019-0198-4","article-title":"Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease","volume":"17","author":"Chang","year":"2019","journal-title":"Thromb J."},{"key":"10.1016\/j.cyto.2021.155593_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00108","article-title":"Sepsis: inflammation is a necessary evil","volume":"7","author":"Nedeva","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cyto.2021.155593_b0350","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cyto.2021.155593_b0355","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0360","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0365","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/thoraxjnl-2011-201437","article-title":"Endothelial cells as regulators of cytokine storms during influenza infection","volume":"67","author":"Gautam","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.cyto.2021.155593_b0370","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0375","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2012.09.039","article-title":"Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection","volume":"435","author":"Oldstone","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.cyto.2021.155593_b0380","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.cell.2011.08.015","article-title":"Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection","volume":"146","author":"Teijaro","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2021.155593_b0385","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2337\/dc06-1793","article-title":"Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity","volume":"30","author":"Esteve","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cyto.2021.155593_b0390","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","author":"Guo","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.cyto.2021.155593_b0395","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b0400","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137799","article-title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness","author":"Wang","year":"2020","journal-title":"JCI Insight."},{"key":"10.1016\/j.cyto.2021.155593_b0405","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1128\/CVI.00636-12","article-title":"Targeting the \u201ccytokine storm\u201d for therapeutic benefit","volume":"20","author":"D'Elia","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0410","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet","author":"Jose","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0415","doi-asserted-by":"crossref","first-page":"R201","DOI":"10.1186\/cc8208","article-title":"Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza","volume":"13","author":"Bermejo-Martin","year":"2009","journal-title":"Crit. Care"},{"key":"10.1016\/j.cyto.2021.155593_b0420","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.2174\/1381612823666170316123736","article-title":"Cytokines induced during influenza virus infection","volume":"23","author":"Betakova","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cyto.2021.155593_b0425","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0430","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1038\/srep03799","article-title":"Characterizing and controlling the inflammatory network during influenza A virus infection","volume":"4","author":"Jin","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b0435","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.icb.7100026","article-title":"A question of self-preservation: immunopathology in influenza virus infection","volume":"85","author":"La Gruta","year":"2007","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.cyto.2021.155593_b0440","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1083\/jcb.201408103","article-title":"Intramembrane binding of VE-cadherin to VEGFR2 and VEGFR3 assembles the endothelial mechanosensory complex","volume":"208","author":"Coon","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.cyto.2021.155593_b0445","doi-asserted-by":"crossref","first-page":"R203","DOI":"10.1186\/cc9324","article-title":"Clinical aspects and cytokine response in severe H1N1 influenza A virus infection","volume":"14","author":"Hagau","year":"2010","journal-title":"Crit. Care"},{"key":"10.1016\/j.cyto.2021.155593_b0450","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1164\/rccm.201309-1616OC","article-title":"Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load","volume":"189","author":"Oshansky","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b0455","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/650581","article-title":"Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection","volume":"50","author":"To","year":"2010","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.cyto.2021.155593_b0460","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2147\/TCRM.S206930","article-title":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study","volume":"15","author":"Zhang","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.cyto.2021.155593_b0465","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4269\/ajtmh.12-0132","article-title":"Clinical factors predictive of pneumonia caused by pandemic 2009 H1N1 influenza virus","volume":"88","author":"Kanchana","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.cyto.2021.155593_b0470","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3906\/sag-1401-111","article-title":"Clinical characteristics of 75 pandemic H1N1 influenza patients from Turkey; risk factors for fatality","volume":"45","author":"Kili\u00e7","year":"2015","journal-title":"Turkish J. Med. Sci."},{"key":"10.1016\/j.cyto.2021.155593_b0475","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.thromres.2010.11.032","article-title":"Serum D-dimer changes and prognostic implication in 2009 novel influenza A(H1N1)","volume":"127","author":"Wang","year":"2011","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cyto.2021.155593_b0480","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12872-015-0095-0","article-title":"Acute cardiac injury events \u226430 days after laboratory-confirmed influenza virus infection among U.S. veterans, 2010\u20132012","volume":"15","author":"Ludwig","year":"2015","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.cyto.2021.155593_b0485","first-page":"1738","article-title":"Acute myocardial infarction and influenza: a meta-analysis of case-control studies","volume":"101","author":"Barnes","year":"2015","journal-title":"Heart (British Cardiac Society)."},{"key":"10.1016\/j.cyto.2021.155593_b0490","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(09)70233-6","article-title":"Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review","volume":"9","author":"Warren-Gash","year":"2009","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.cyto.2021.155593_b0495","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/ijcp.12646","article-title":"Influenza, influenza-like symptoms and their association with cardiovascular risks: a systematic review and meta-analysis of observational studies","volume":"69","author":"Kwok","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.cyto.2021.155593_b0500","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.RES.0000251962.44753.7f","article-title":"Inflammation and coagulation in the cardiovascular system","volume":"99","author":"Marsden","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.cyto.2021.155593_b0505","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2013-09-526277","article-title":"Multiple roles of the coagulation protease cascade during virus infection","volume":"123","author":"Antoniak","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0510","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4161\/viru.25779","article-title":"Endothelial activation and dysfunction in the pathogenesis of influenza A virus infection","volume":"4","author":"Armstrong","year":"2013","journal-title":"Virulence."},{"key":"10.1016\/j.cyto.2021.155593_b0515","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201406-1031OC","article-title":"Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis","volume":"191","author":"L\u00ea","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b0520","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/cmi.2016.1","article-title":"Aberrant coagulation causes a hyper-inflammatory response in severe influenza pneumonia","volume":"13","author":"Yang","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0525","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2169\/internalmedicine.50.4620","article-title":"H1N1 influenza (swine flu)-associated thrombotic microangiopathy with a markedly high plasma ratio of von willebrand factor to ADAMTS13","volume":"50","author":"Akiyama","year":"2011","journal-title":"Intern. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0530","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2013-07-515536","article-title":"Influenza virus H1N1 activates platelets through Fc\u03b3RIIA signaling and thrombin generation","volume":"123","author":"Boilard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0535","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","article-title":"Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury","volume":"133","author":"Imai","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.cyto.2021.155593_b0540","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood-2008-02-137901","article-title":"A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells","volume":"113","author":"Shibamiya","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003848","article-title":"DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway","volume":"10","author":"Tsai","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cyto.2021.155593_b0550","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0555","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s11033-011-0846-7","article-title":"Antiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection","volume":"39","author":"Liu","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b0560","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fmicb.2014.00653","article-title":"Influenza virus and endothelial cells: a species specific relationship","volume":"5","author":"Short","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.cyto.2021.155593_b0565","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2017.10.020","article-title":"The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection","volume":"148","author":"Sarvestani","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.cyto.2021.155593_b0570","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1084\/jem.20081667","article-title":"Inflammasome recognition of influenza virus is essential for adaptive immune responses","volume":"206","author":"Ichinohe","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0575","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/viru.2.2.15480","article-title":"HMGB1 release by inflammasomes","volume":"2","author":"Vande Walle","year":"2011","journal-title":"Virulence."},{"key":"10.1016\/j.cyto.2021.155593_b0580","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw."},{"key":"10.1016\/j.cyto.2021.155593_b0585","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1073\/pnas.1400593111","article-title":"Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection","volume":"111","author":"Teijaro","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.cyto.2021.155593_b0590","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12026-011-8240-z","article-title":"Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm","volume":"51","author":"Walsh","year":"2011","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cyto.2021.155593_b0595","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1128\/JVI.00464-14","article-title":"Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy","volume":"88","author":"Walsh","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.cyto.2021.155593_b0600","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1038\/s41598-019-41760-7","article-title":"Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: a potential therapy against pathogenic influenza virus","volume":"9","author":"Zhao","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b0605","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1465-9921-6-135","article-title":"Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells","volume":"6","author":"Chan","year":"2005","journal-title":"Respir. Res."},{"key":"10.1016\/j.cyto.2021.155593_b0610","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(02)11772-7","article-title":"Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?","volume":"360","author":"Cheung","year":"2002","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.cyto.2021.155593_b0615","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.it.2009.09.004","article-title":"Innate immune responses to influenza A H5N1: friend or foe?","volume":"30","author":"Peiris","year":"2009","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0620","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014"},{"key":"10.1016\/j.cyto.2021.155593_b0625","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2021.155593_b0630","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.4049\/jimmunol.166.6.4042","article-title":"Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during <em>Escherichia coli<\/em> pneumonia in mice","volume":"166","author":"Mizgerd","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0635","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-\u03b1 signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.cyto.2021.155593_b0640","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1101\/gad.244749.114","article-title":"Network dynamics determine the autocrine and paracrine signaling functions of TNF","volume":"28","author":"Caldwell","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.cyto.2021.155593_b0645","first-page":"669","article-title":"Role of cytokines as a double-edged sword in sepsis","volume":"27","author":"Chaudhry","year":"2013","journal-title":"In Vivo (Athens, Greece)."},{"key":"10.1016\/j.cyto.2021.155593_b0650","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1096\/fasebj.6.8.1592209","article-title":"Cytokine regulation of endothelial cell function","volume":"6","author":"Mantovani","year":"1992","journal-title":"FASEB J.: Off. Publ. Feder. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.cyto.2021.155593_b0655","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00395-008-0733-0","article-title":"The role of inflammatory cytokines in endothelial dysfunction","volume":"103","author":"Zhang","year":"2008","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.cyto.2021.155593_b0660","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L","article-title":"Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology","volume":"31","author":"Hussell","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0665","doi-asserted-by":"crossref","first-page":"R301","DOI":"10.1186\/cc13171","article-title":"Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice","volume":"17","author":"Shi","year":"2013","journal-title":"Crit. Care (London, England)."},{"key":"10.1016\/j.cyto.2021.155593_b0670","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/cei.12736","article-title":"Differential evolution of peripheral cytokine levels in symptomatic and asymptomatic responses to experimental influenza virus challenge","volume":"183","author":"McClain","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004250","article-title":"Infection with MERS-CoV causes lethal pneumonia in the common marmoset","volume":"10","author":"Falzarano","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cyto.2021.155593_b0680","doi-asserted-by":"crossref","first-page":"32538","DOI":"10.1038\/srep32538","article-title":"Suppressor of cytokine signaling 3 plays an important role in porcine circovirus type 2 subclinical infection by downregulating proinflammatory responses","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b0685","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/jmv.24138","article-title":"Induction of interleukin-1 beta (IL-1\u03b2) is a critical component of lung inflammation during influenza A (H1N1) virus infection","volume":"87","author":"Kim","year":"2015","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cyto.2021.155593_b0690","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1128\/JVI.79.10.6441-6448.2005","article-title":"Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection","volume":"79","author":"Schmitz","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.cyto.2021.155593_b0695","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00281-017-0636-y","article-title":"New fronts emerge in the influenza cytokine storm","volume":"39","author":"Guo","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.cyto.2021.155593_b0700","doi-asserted-by":"crossref","first-page":"27912","DOI":"10.1038\/srep27912","article-title":"Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition","volume":"6","author":"Tate","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b0705","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/mi.2012.2","article-title":"Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung","volume":"5","author":"Dienz","year":"2012","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0710","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/eji.201243018","article-title":"Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology","volume":"43","author":"Lauder","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0715","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1084\/jem.20081571","article-title":"The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells","volume":"206","author":"Dienz","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0720","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01843","article-title":"Influenza virus-induced robust expression of SOCS3 contributes to excessive production of IL-6","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0725","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.cyto.2021.155593_b0730","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.01057","article-title":"The role of interleukin 6 during viral infections","volume":"10","author":"Velazquez-Salinas","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.cyto.2021.155593_b0735","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-019-0356-0","article-title":"Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: fusing experimental insights and dynamic modelling","volume":"17","author":"Reeh","year":"2019","journal-title":"Cell Commun. Sig."},{"key":"10.1016\/j.cyto.2021.155593_b0740","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/imt-2019-0074","article-title":"Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies","volume":"11","author":"Khadka","year":"2019","journal-title":"Immunotherapy."},{"key":"10.1016\/j.cyto.2021.155593_b0745","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cyto.2021.155593_b0750","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2217\/imt-2017-0026","article-title":"Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers","volume":"9","author":"O\u2019Hara","year":"2017","journal-title":"Immunotherapy."},{"key":"10.1016\/j.cyto.2021.155593_b0755","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fphys.2014.00175","article-title":"endothelial cell function, and vascular diseases","volume":"5","author":"Tang","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.cyto.2021.155593_b0760","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2021.155593_b0765","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11427-016-5035-4","article-title":"An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.cyto.2021.155593_b0770","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0775","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomarker Res."},{"key":"10.1016\/j.cyto.2021.155593_b0780","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0785","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0790","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b0795","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.cyto.2021.155593_b0800","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cyto.2021.155593_b0805","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0810","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01529","article-title":"Controlling cytokine release syndrome to harness the full potential of CAR-based cellular therapy","volume":"9","author":"Thakar","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cyto.2021.155593_b0815","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0820","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00007890-199004000-00009","article-title":"In vivo cell activation following OKT3 administration. systemic cytokine release and modulation by corticosteroids","volume":"49","author":"Chatenoud","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.cyto.2021.155593_b0825","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0830","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1080\/10428194.2017.1387905","article-title":"Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL","volume":"59","author":"Roberts","year":"2017","journal-title":"Leukemia Lymphoma."},{"key":"10.1016\/j.cyto.2021.155593_b0835","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0840","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.cyto.2021.155593_b0845","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0850","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy."},{"key":"10.1016\/j.cyto.2021.155593_b0855","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0860","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0865","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0870","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.immunol.021908.132532","article-title":"Alternative activation of macrophages: an immunologic functional perspective","volume":"27","author":"Martinez","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0875","doi-asserted-by":"crossref","first-page":"H39","DOI":"10.1152\/ajpheart.00490.2015","article-title":"Endothelial PPAR-\u03b3 provides vascular protection from IL-1\u03b2-induced oxidative stress","volume":"310","author":"Mukohda","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.cyto.2021.155593_b0880","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4049\/jimmunol.167.6.3435","article-title":"The IL-6-soluble IL-6R\u03b1 autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin","volume":"167","author":"Marin","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0885","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5301\/jsrd.5000265","article-title":"Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis","volume":"2","author":"Choy","year":"2017","journal-title":"J. Scleroderma Related Disord."},{"key":"10.1016\/j.cyto.2021.155593_b0890","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.7150\/ijbs.4828","article-title":"The pathological and physiological roles of IL-6 amplifier activation","volume":"8","author":"Murakami","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cyto.2021.155593_b0895","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/157340308785160570","article-title":"Roles of IL-6-gp130 signaling in vascular inflammation","volume":"4","author":"Hou","year":"2008","journal-title":"Curr. Cardiol. Rev."},{"key":"10.1016\/j.cyto.2021.155593_b0900","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.4049\/jimmunol.1103613","article-title":"IL-6 amplifier, NF-\u03baB\u2013triggered positive feedback for IL-6 signaling, in grafts is involved in allogeneic rejection responses","volume":"189","author":"Lee","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0905","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12969-016-0130-4","article-title":"Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome","volume":"15","author":"Bracaglia","year":"2017","journal-title":"Pediatr Rheumatol Online J."},{"key":"10.1016\/j.cyto.2021.155593_b0910","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11048","article-title":"Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"1","author":"Eloseily","year":"2019","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b0915","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jha2.57","article-title":"Etoposide-based treatment of adult HLH is associated with high biochemical response but poor survival outcomes","volume":"1","author":"Nicholson","year":"2020","journal-title":"eJHaem"},{"key":"10.1016\/j.cyto.2021.155593_b0920","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH)","author":"Horne","year":"2021","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b0925","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.cyto.2021.155593_b0930","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/cei.13057","article-title":"H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome","volume":"191","author":"Ruscitti","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0935","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b0940","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/rheumatology\/keu524","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3","volume":"54","author":"Put","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155593_b0945","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2249.2003.02237.x","article-title":"Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis","volume":"133","author":"Takada","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b0950","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2011.11.046","article-title":"Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children","volume":"160","author":"Xu","year":"2012","journal-title":"J. Pediatrics."},{"key":"10.1016\/j.cyto.2021.155593_b0960","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1182\/blood-2018-02-828186","article-title":"Fire behind the fury: IL-18 and MAS","volume":"131","author":"McClain","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b0965","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b0970","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mpd.2003.110","article-title":"Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"142","author":"Grom","year":"2003","journal-title":"J. Pediat."},{"key":"10.1016\/j.cyto.2021.155593_b0975","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar1453","article-title":"Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"7","author":"Villanueva","year":"2005","journal-title":"Arthritis Res. Therapy."},{"key":"10.1016\/j.cyto.2021.155593_b0980","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cytogfr.2014.10.001","article-title":"Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders","volume":"26","author":"Brisse","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2021.155593_b0985","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","article-title":"Macrophage activation syndrome: advances towards understanding pathogenesis","volume":"22","author":"Grom","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b0990","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cyto.2018.05.017","article-title":"Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis","volume":"110","author":"Sakumura","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2021.155593_b0995","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1182\/blood-2010-08-300046","article-title":"Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis","volume":"117","author":"Sumegi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b1000","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3201\/eid2502.181326","article-title":"Macrophage activation marker soluble CD163 associated with fatal and severe ebola virus disease in humans(1)","volume":"25","author":"McElroy","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cyto.2012.05.003","article-title":"Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages","volume":"60","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2021.155593_b1015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2019.00055","article-title":"Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis","volume":"10","author":"Karakike","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1020","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)."},{"key":"10.1016\/j.cyto.2021.155593_b1025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OARRR.S151013","article-title":"Macrophage activation syndrome: early diagnosis is key","volume":"10","author":"Lerkvaleekul","year":"2018","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1030","series-title":"Macrophage Activation Syndrome","author":"Grom","year":"2016"},{"key":"10.1016\/j.cyto.2021.155593_b1035","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1172\/JCI119379","article-title":"3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima","volume":"99","author":"Hazen","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2021.155593_b1040","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/art.38793","article-title":"Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis","volume":"66","author":"Kaufman","year":"2014","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)."},{"key":"10.1016\/j.cyto.2021.155593_b1045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","article-title":"Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis","volume":"49","author":"Vastert","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2021.155593_b1050","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cyto.2021.155593_b1055","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ng.3066","article-title":"Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation","volume":"46","author":"Romberg","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cyto.2021.155593_b1060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","article-title":"The genetics of macrophage activation syndrome","volume":"21","author":"Schulert","year":"2020","journal-title":"Genes Immun."},{"key":"10.1016\/j.cyto.2021.155593_b1065","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12887-019-1444-4","article-title":"Rare cause of Hemophagocytic Lymphohistiocytosis due to mutation in PRF1 and SH2D1A genes in two children \u2013 a case report with a review","volume":"19","author":"Sheth","year":"2019","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.cyto.2021.155593_b1070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ajhg.2009.09.005","article-title":"Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11","volume":"85","author":"zur Stadt","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.cyto.2021.155593_b1075","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.V78.11.2918.2918","article-title":"Hypercytokinemia in familial hemophagocytic lymphohistiocytosis","volume":"78","author":"Henter","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b1080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1084\/jem.20140964","article-title":"Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time","volume":"212","author":"Jenkins","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1085","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.1501284","article-title":"A Heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis","volume":"196","author":"Zhang","year":"2016","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"10.1016\/j.cyto.2021.155593_b1090","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ppul.22778","article-title":"Macrophage activation syndrome induced by A\/H1N1 influenza in cystic fibrosis","volume":"49","author":"Casciaro","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.cyto.2021.155593_b1095","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fimmu.2017.01102","article-title":"How viruses contribute to the pathogenesis of hemophagocytic lymphohistiocytosis","volume":"8","author":"Brisse","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1100","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","article-title":"Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza","volume":"213","author":"Schulert","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1105","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/art.22981","article-title":"Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome","volume":"56","author":"Fall","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155593_b1110","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3899\/jrheum.121233","article-title":"Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome","volume":"40","author":"Strippoli","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","volume":"22","author":"Henderson","year":"2020","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.cyto.2021.155593_b1125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000324176","article-title":"Natural killer cell responses to viral infection","volume":"3","author":"Brandstadter","year":"2011","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.cyto.2021.155593_b1130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/art.20198","article-title":"Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?","volume":"50","author":"Grom","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155593_b1135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226043","article-title":"The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis","volume":"14","author":"Prencipe","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2021.155593_b1140","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3899\/jrheum.090662","article-title":"Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases","volume":"37","author":"Maruyama","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1145","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti\u2013interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155593_b1150","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1002\/art.34604","article-title":"The limited role of interferon-\u03b3 in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness","volume":"64","author":"Sikora","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155593_b1155","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.22644","article-title":"Specific gene expression profiles in systemic juvenile idiopathic arthritis","volume":"56","author":"Ogilvie","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155593_b1160","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2018.00181","article-title":"Macrophage activation marker neopterin: a candidate biomarker for treatment response and relapse in visceral leishmaniasis","volume":"8","author":"Kip","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.cyto.2021.155593_b1165","first-page":"44","article-title":"The clinical significance of serum neopterin and adenosine deaminase in patients with secondary hemophagocytic lymphohistiocytosis","volume":"54","author":"Chen","year":"2015","journal-title":"Zhonghua nei ke za zhi."},{"key":"10.1016\/j.cyto.2021.155593_b1170","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/CVI.00306-10","article-title":"Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome","volume":"18","author":"Ibarra","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1175","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2021.155593_b1180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun."},{"key":"10.1016\/j.cyto.2021.155593_b1185","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2021.155593_b1190","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V89.11.4100","article-title":"Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis","volume":"89","author":"Osugi","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b1195","doi-asserted-by":"crossref","unstructured":"F.D. Benedetti, P. Brogan, A. Grom, P. Quartier, R. Schneider, K.D. Graaf, et al., OP0204 Emapalumab, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). Oral Presentations: BMJ Publishing Group Ltd and European League Against Rheumatism (2019)..","DOI":"10.1136\/annrheumdis-2019-eular.3341"},{"key":"10.1016\/j.cyto.2021.155593_b1200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","article-title":"Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections","volume":"3","author":"Lounder","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.cyto.2021.155593_b1205","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/embor.2010.93","article-title":"Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production","volume":"11","author":"Masters","year":"2010","journal-title":"EMBO Rep."},{"key":"10.1016\/j.cyto.2021.155593_b1210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/cmi.2016.25","article-title":"Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses","volume":"14","author":"Mayer-Barber","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: Biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2021.155593_b1220","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.berh.2014.03.002","article-title":"Macrophage activation syndrome and cytokine-directed therapies","volume":"28","author":"Schulert","year":"2014","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1225","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2147\/DDDT.S114532","article-title":"The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives","volume":"12","author":"Toplak","year":"2018","journal-title":"Drug Des. Deve. Therapy."},{"key":"10.1016\/j.cyto.2021.155593_b1230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.cyto.2021.155593_b1235","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still's disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155593_b1240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/(SICI)1096-911X(199607)27:1<21::AID-MPO5>3.0.CO;2-W","article-title":"Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis","volume":"27","author":"Henter","year":"1996","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.cyto.2021.155593_b1245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","article-title":"Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically Ill children*","volume":"15","author":"Rajasekaran","year":"2014","journal-title":"Pediatric Crit. Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b1250","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b1255","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0885066617711386","article-title":"Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically Ill adult patients with hemophagocytic lymphohistiocytosis","volume":"34","author":"Wohlfarth","year":"2017","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.cyto.2021.155593_b1260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cyto.2011.07.006","article-title":"IL-1 acts on T cells to enhance the magnitude of in vivo immune responses","volume":"56","author":"Ben-Sasson","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2021.155593_b1265","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1101\/sqb.2013.78.021246","article-title":"IL-1\u03b2 strikingly enhances antigen-driven CD4 and CD8 T-cell responses","volume":"78","author":"Ben-Sasson","year":"2013","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.cyto.2021.155593_b1270","doi-asserted-by":"crossref","first-page":"17005","DOI":"10.1038\/s41598-018-35429-w","article-title":"IL-1\u03b2- and IL-4-polarized macrophages have opposite effects on adipogenesis of intramuscular fibro-adipogenic progenitors in humans","volume":"8","author":"Moratal","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b1275","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41232-019-0101-5","article-title":"The role of interleukin-1 in general pathology","volume":"39","author":"Kaneko","year":"2019","journal-title":"Inflamm Regen."},{"key":"10.1016\/j.cyto.2021.155593_b1280","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","article-title":"Elevated serum levels of free interleukin-18 in adult-onset Still's disease","volume":"55","author":"Girard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155593_b1285","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","article-title":"Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome","volume":"106","author":"Mazodier","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b1290","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2021.155593_b1295","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin. Immunol. (Orlando, Fla)."},{"key":"10.1016\/j.cyto.2021.155593_b1300","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10875-008-9217-0","article-title":"Interleukin-18 binding protein in the sera of patients with Wegener\u2019s granulomatosis","volume":"29","author":"Novick","year":"2008","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1305","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaut.2009.08.002","article-title":"High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein","volume":"34","author":"Novick","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cyto.2021.155593_b1310","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","article-title":"Interleukin-18 regulates both Th1 and Th2 responses","volume":"19","author":"Nakanishi","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1315","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1073\/pnas.1203543109","article-title":"Regulation of innate CD8<sup>+<\/sup> T-cell activation mediated by cytokines","volume":"109","author":"Freeman","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cyto.2021.155593_b1320","first-page":"1","article-title":"The activation of bystander CD8+ T cells and their roles in viral infection","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1325","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-019-0570-3","article-title":"T cell receptor and cytokine signal integration in CD8+ T cells is mediated by the protein Themis","volume":"21","author":"Brzostek","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1330","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1128\/IAI.01315-08","article-title":"Interleukin-18-related genes are induced during the contraction phase but do not play major roles in regulating the dynamics or function of the T-cell response to Listeria monocytogenes infection","volume":"77","author":"Haring","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cyto.2021.155593_b1335","doi-asserted-by":"crossref","first-page":"e2404","DOI":"10.1371\/journal.pone.0002404","article-title":"An IFN-gamma-IL-18 signaling loop accelerates memory CD8+ T cell proliferation","volume":"3","author":"Iwai","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2021.155593_b1340","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1189\/jlb.0706431","article-title":"Protection of CD8+ T cells from activation-induced cell death by IL-18","volume":"82","author":"Li","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cyto.2021.155593_b1345","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.immuni.2009.09.015","article-title":"A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy","volume":"31","author":"Turtle","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2021.155593_b1350","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trsl.2015.06.006","article-title":"Targeting the inflammasome in rheumatic diseases","volume":"167","author":"McCoy","year":"2016","journal-title":"Transl. Res.: J. Lab. Clin. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1355","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.12607","article-title":"The NLRC4 inflammasome","volume":"281","author":"Duncan","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2021.155593_b1360","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2012.09.012","article-title":"Anti-viral CD8 T cells and the cytokines that they love","volume":"435","author":"Cox","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.cyto.2021.155593_b1365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-018-1800-z","article-title":"Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease","volume":"21","author":"Hu","year":"2019","journal-title":"Arthritis Res. Therapy."},{"key":"10.1016\/j.cyto.2021.155593_b1370","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3899\/jrheum.161354","article-title":"Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease","volume":"44","author":"Hsieh","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1375","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/s100100097","article-title":"The inflammasome in host defense","volume":"10","author":"Chen","year":"2010","journal-title":"Sensors (Basel, Switzerland)."},{"key":"10.1016\/j.cyto.2021.155593_b1380","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/microorganisms7060183","article-title":"Epstein-barr virus and innate immunity: friends or foes?","volume":"7","author":"Jangra","year":"2019","journal-title":"Microorganisms."},{"key":"10.1016\/j.cyto.2021.155593_b1385","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1615\/CritRevImmunol.v30.i5.50","article-title":"Inflammasomes and their activation","volume":"30","author":"Khare","year":"2010","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1390","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2021.155593_b1395","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/art.1780340912","article-title":"Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis","volume":"34","author":"de Benedetti","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cyto.2021.155593_b1400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020014","article-title":"Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients","volume":"6","author":"Lasigli\u00e8","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2021.155593_b1405","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","article-title":"Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-\u03b3-producing lymphocytes and IL-6- and TNF-\u03b1-producing macrophages","volume":"105","author":"Billiau","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b1410","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood.V76.12.2466.2466","article-title":"Transforming growth factor beta downregulates interleukin-1 (IL-1)- induced IL-6 production by human monocytes","volume":"76","author":"Musso","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b1415","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/1521-4141(200010)30:10<3057::AID-IMMU3057>3.0.CO;2-P","article-title":"Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1\u03b2","volume":"30","author":"Netea","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1420","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-016-0593-9","article-title":"Biologics in pediatric rheumatology: quo vadis?","volume":"18","author":"Sterba","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.cyto.2021.155593_b1425","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1430","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/pr.2013.187","article-title":"Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis","volume":"75","author":"Correll","year":"2014","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.cyto.2021.155593_b1435","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pbc.21019","article-title":"Etanercept for therapy-resistant macrophage activation syndrome","volume":"50","author":"Makay","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.cyto.2021.155593_b1440","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00296-011-2319-7","article-title":"Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome","volume":"33","author":"Buonuomo","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cyto.2021.155593_b1445","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2021.155593_b1450","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/01.rhu.0000217154.47562.91","article-title":"Macrophage activation syndrome in nine patients: three adults and six children","volume":"12","author":"Sterba","year":"2006","journal-title":"JCR J. Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1455","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00124743-200108000-00013","article-title":"Worsening of macrophage activation syndrome in a patient with adult onset still\u2019s disease after initiation of etanercept therapy","volume":"7","author":"Stern","year":"2001","journal-title":"JCR J. Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1460","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4049\/jimmunol.1100625","article-title":"Production of TNF-\u03b1 in macrophages activated by T cells, compared with lipopolysaccharide, uses distinct IL-10\u2013dependent regulatory mechanism","volume":"188","author":"Agbanoma","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1465","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000163664","article-title":"Regulation of M-CSF expression by M-CSF: role of protein kinase C and transcription factor NF kappa B","volume":"59","author":"Brach","year":"1991","journal-title":"Pathobiol. J. Immunopathol. Mol. Cell. Biol."},{"key":"10.1016\/j.cyto.2021.155593_b1470","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/dna.2011.1357","article-title":"Macrophage colony stimulating factor regulation by nuclear factor kappa B: a relevant pathway in human immunodeficiency virus type 1 infected macrophages","volume":"31","author":"Kogan","year":"2012","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.cyto.2021.155593_b1475","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1084\/jem.20160499","article-title":"Autonomous TNF is critical for in vivo monocyte survival in steady state and inflammation","volume":"214","author":"Wolf","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1480","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.4049\/jimmunol.0900105","article-title":"A pivotal role of endothelial-specific NF-\u03baB signaling in the pathogenesis of septic shock and septic vascular dysfunction","volume":"183","author":"Ding","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1485","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1172\/JCI66843","article-title":"Linking endothelial dysfunction with endothelial cell activation","volume":"123","author":"Liao","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cyto.2021.155593_b1490","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00085","article-title":"Cell type-specific roles of NF-\u03baB linking inflammation and thrombosis","volume":"10","author":"Mussbacher","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1495","doi-asserted-by":"crossref","first-page":"16556","DOI":"10.1073\/pnas.1218219110","article-title":"NF-\u03baB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-\u03baB in immune-mediated diseases","volume":"110","author":"Sehnert","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cyto.2021.155593_b1500","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"van der Poll","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1505","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.4049\/jimmunol.1800042","article-title":"The alternative NF-\u03baB pathway in regulatory T cell homeostasis and suppressive function","volume":"200","author":"Grinberg-Bleyer","year":"2018","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"10.1016\/j.cyto.2021.155593_b1510","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.4049\/jimmunol.1102429","article-title":"Chronic activation of the kinase IKK\u03b2 impairs T cell function and survival","volume":"189","author":"Krishna","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1515","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12033","article-title":"NF-\u03baB: roles and regulation in different CD4(+) T-cell subsets","volume":"252","author":"Oh","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2021.155593_b1520","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","article-title":"Activation of apoptosis signalling pathways by reactive oxygen species","volume":"1863","author":"Redza-Dutordoir","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA) \u2013 Mol. Cell Res."},{"key":"10.1016\/j.cyto.2021.155593_b1525","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.4110\/in.2018.18.e14","article-title":"The role of reactive oxygen species in regulating T cell-mediated immunity and disease","volume":"18","author":"Yarosz","year":"2018","journal-title":"Immune Netw."},{"key":"10.1016\/j.cyto.2021.155593_b1530","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbrc.2013.06.118","article-title":"Mechanisms underlying mouse TNF-alpha stimulated neutrophil derived microparticle generation","volume":"437","author":"Johnson","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cyto.2021.155593_b1535","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1189\/jlb.0103038","article-title":"Aggregation of \u03b22 integrins activates human neutrophils through the I\u03baB\/NF-\u03baB pathway","volume":"75","author":"Kim","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cyto.2021.155593_b1540","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/jpet.112.202879","article-title":"Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs","volume":"345","author":"Lapponi","year":"2013","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"10.1016\/j.cyto.2021.155593_b1545","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.3390\/nu5083131","article-title":"Vitamin C: a novel regulator of neutrophil extracellular trap formation","volume":"5","author":"Mohammed","year":"2013","journal-title":"Nutrients."},{"key":"10.1016\/j.cyto.2021.155593_b1550","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Targeted Therapy."},{"key":"10.1016\/j.cyto.2021.155593_b1555","doi-asserted-by":"crossref","first-page":"118617","DOI":"10.1016\/j.lfs.2020.118617","article-title":"Preventing the development of severe COVID-19 by modifying immunothrombosis","volume":"264","author":"Morris","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2021.155593_b1560","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin. Sci. (London, England: 1979)"},{"key":"10.1016\/j.cyto.2021.155593_b1565","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","article-title":"Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer","volume":"23","author":"Liang","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cyto.2021.155593_b1570","article-title":"Sphingosine-1-phosphate","volume":"2","author":"Theiss","year":"2013","journal-title":"JAKSTAT."},{"key":"10.1016\/j.cyto.2021.155593_b1575","doi-asserted-by":"crossref","first-page":"80579","DOI":"10.18632\/oncotarget.13013","article-title":"Sphk1 promotes breast epithelial cell proliferation via NF-\u03baB-p65-mediated cyclin D1 expression","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.cyto.2021.155593_b1580","doi-asserted-by":"crossref","first-page":"10279","DOI":"10.3748\/wjg.v20.i30.10279","article-title":"STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer","volume":"20","author":"Nguyen","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cyto.2021.155593_b1585","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbior.2015.09.001","article-title":"Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation","volume":"60","author":"Pyne","year":"2016","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.cyto.2021.155593_b1590","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1158\/1078-0432.CCR-10-0720","article-title":"Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K\/Akt\/NF-\u03baB pathway in human non-small cell lung cancer","volume":"17","author":"Song","year":"2011","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cyto.2021.155593_b1595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2011.00022","article-title":"A Four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases","volume":"2","author":"Murakami","year":"2011","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1600","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/01.tp.0000698524.83201.9b","article-title":"Role of IL-6 and IL-17 mediated inflammation amplifier loop in chronic antibody-mediated rejection (CABMR)","volume":"104","author":"Singh","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.cyto.2021.155593_b1605","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cyto.2021.155593_b1610","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci. Signaling"},{"key":"10.1016\/j.cyto.2021.155593_b1615","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1007\/s00018-008-8064-8","article-title":"TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme","volume":"65","author":"Verstrepen","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cyto.2021.155593_b1620","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-14-3382","article-title":"IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-\u03baB Activation","volume":"22","author":"Zhuang","year":"2016","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.cyto.2021.155593_b1625","article-title":"Role for anti-cytokine therapies in severe coronavirus disease 2019","volume":"2","author":"Buckley","year":"2020","journal-title":"Crit. Care Explor."},{"key":"10.1016\/j.cyto.2021.155593_b1630","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1541-7786.MCR-17-0221","article-title":"NF\u03baB-mediated invasiveness in CD133(+) pancreatic TICs is regulated by autocrine and paracrine activation of IL1 signaling","volume":"16","author":"Nomura","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cyto.2021.155593_b1635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1640","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00011-014-0756-y","article-title":"NLRP3 inflammasome activation and interleukin-1\u03b2 release in macrophages require calcium but are independent of calcium-activated NADPH oxidases","volume":"63","author":"Rada","year":"2014","journal-title":"Inflammation Res.: Off. J. Eur. Histamine Res. Soc. [et al]."},{"key":"10.1016\/j.cyto.2021.155593_b1645","doi-asserted-by":"crossref","first-page":"25900","DOI":"10.1074\/jbc.M707692200","article-title":"Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT\/IkappaB kinase alpha pathway targeting activator protein-1","volume":"283","author":"Cahill","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2021.155593_b1650","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179065","article-title":"Proteome profiling in IL-1\u03b2 and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis","volume":"12","author":"Mohr","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cyto.2021.155593_b1655","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1479-5876-3-37","article-title":"Interleukin-1\u03b2 induced vascular permeability is dependent on induction of endothelial Tissue Factor (TF) activity","volume":"3","author":"Puhlmann","year":"2005","journal-title":"J Transl Med."},{"key":"10.1016\/j.cyto.2021.155593_b1660","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cyto.2021.155593_b1665","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41232-020-00131-w","article-title":"Macrophage activation syndrome and COVID-19","volume":"40","author":"Otsuka","year":"2020","journal-title":"Inflamm Regen."},{"key":"10.1016\/j.cyto.2021.155593_b1670","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cyto.2021.155593_b1675","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cyto.2021.155593_b1680","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1685","doi-asserted-by":"crossref","first-page":"9862","DOI":"10.1073\/pnas.1307575110","article-title":"Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer","volume":"110","author":"Hu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.cyto.2021.155593_b1690","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","article-title":"Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis","volume":"58","author":"Doeleman","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2021.155593_b1695","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.cyto.2021.155593_b1700","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with covid-19 pneumonia","volume":"384","author":"Salama","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1705","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe covid-19 pneumonia","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1710","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial","author":"Horby","year":"2021","journal-title":"medRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b1715","article-title":"Interleukin-6 receptor inhibition in covid-19 \u2014 cooling the inflammatory soup","author":"Rubin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106103","article-title":"Tocilizumab for severe COVID-19: a systematic review and meta-analysis","volume":"56","author":"Lan","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cyto.2021.155593_b1725","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2021.155593_b1730","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102999","article-title":"Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study","volume":"60","author":"Masi\u00e1","year":"2020","journal-title":"EBioMedicine."},{"key":"10.1016\/j.cyto.2021.155593_b1735","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.celrep.2014.07.008","article-title":"IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function","volume":"8","author":"B\u00f6ttcher","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.cyto.2021.155593_b1740","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","article-title":"The effects of IL-6 on CD4 T cell responses","volume":"130","author":"Dienz","year":"2009","journal-title":"Clin. Immunol. (Orlando, Fla)."},{"key":"10.1016\/j.cyto.2021.155593_b1745","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1750","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Therap. Adv. Musculoskeletal Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1755","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/rheumatology\/key280","article-title":"The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2021.155593_b1760","doi-asserted-by":"crossref","first-page":"7492904","DOI":"10.1155\/2018\/7492904","article-title":"Are Janus kinase inhibitors superior over classic biologic agents in RA patients?","volume":"2018","author":"Kotyla","year":"2018","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.cyto.2021.155593_b1765","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.cyto.2021.155593_b1770","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","article-title":"Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study","volume":"60","author":"Rodriguez-Garcia","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cyto.2021.155593_b1775","article-title":"Use of baricitinib in patients with moderate and severe COVID-19","author":"Titanji","year":"2020","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.cyto.2021.155593_b1780","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","author":"Kalil","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2021.155593_b1785","article-title":"The protective effect of rheumatic disease agents in COVID-19","volume":"101659","author":"Valenzuela-Almada","year":"2021","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1790","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.COVID-19-PO-002","article-title":"Abstract PO-002: RUXCOVID: A phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19\u2013associated cytokine storm","volume":"26","author":"Han","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2021.155593_b1795","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/cei.12234","article-title":"Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis","volume":"175","author":"Migita","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.cyto.2021.155593_b1800","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1805","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","article-title":"Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study","volume":"36","author":"Okano","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cyto.2021.155593_b1810","doi-asserted-by":"crossref","unstructured":"G.E. Fragoulis, I.B. McInnes, S. Siebert, JAK-inhibitors, New players in the field of immune-mediated diseases, beyond rheumatoid arthritis, Rheumatology. 58 (2019) i43\u2013i54..","DOI":"10.1093\/rheumatology\/key276"},{"key":"10.1016\/j.cyto.2021.155593_b1815","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res. Therapy."},{"key":"10.1016\/j.cyto.2021.155593_b1820","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/vaccines4030023","article-title":"Viral Inhibition of the IFN-induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists","volume":"4","author":"Fleming","year":"2016","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.cyto.2021.155593_b1825","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s00018-017-2520-2","article-title":"Advances in anti-viral immune defence: revealing the importance of the IFN JAK\/STAT pathway","volume":"74","author":"Raftery","year":"2017","journal-title":"Cell. Mol. Life Sci.: CMLS."},{"key":"10.1016\/j.cyto.2021.155593_b1830","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/272359","article-title":"The complex role of STAT3 in viral infections","volume":"2015","author":"Kuchipudi","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.cyto.2021.155593_b1835","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2217\/fvl-2018-0033","article-title":"STAT3 roles in viral infection: antiviral or proviral?","volume":"13","author":"Chang","year":"2018","journal-title":"Future Virol."},{"key":"10.1016\/j.cyto.2021.155593_b1840","doi-asserted-by":"crossref","first-page":"2001919","DOI":"10.1183\/13993003.01919-2020","article-title":"JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk","volume":"56","author":"Mehta","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cyto.2021.155593_b1845","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.01.023","article-title":"The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer","volume":"154","author":"Gram","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cyto.2021.155593_b1850","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"MAbs."},{"key":"10.1016\/j.cyto.2021.155593_b1855","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/20009666.2018.1428023","article-title":"Canakinumab and cardiovascular outcomes: results of the CANTOS trial","volume":"8","author":"Shah","year":"2018","journal-title":"J. Community Hosp Intern. Med. Perspect."},{"key":"10.1016\/j.cyto.2021.155593_b1860","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40259-015-0123-8","article-title":"Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis","volume":"29","author":"Hoy","year":"2015","journal-title":"BioDrugs."},{"key":"10.1016\/j.cyto.2021.155593_b1865","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for Treatment of adult-onset still\u2019s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1870","article-title":"Canakinumab in a subgroup of patients with COVID-19","volume":"2","author":"Ucciferri","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1875","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/clc.23451","article-title":"Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)","volume":"43","author":"Sheng","year":"2020","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.cyto.2021.155593_b1880","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/CVI.00175-10","article-title":"Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study","volume":"17","author":"Chioato","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1885","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2020-217419","article-title":"Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial","volume":"79","author":"Ozen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1890","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cyto.2021.155593_b1895","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-19-3176","article-title":"Inhibition of IL1\u03b2 by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial","volume":"80","author":"Wong","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.cyto.2021.155593_b1900","first-page":"3959","article-title":"IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and \u03b2-(1\u20133), (1\u20136)-D-glucan","volume":"30","author":"Harnack","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cyto.2021.155593_b1905","article-title":"The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature","author":"Giacomelli","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1910","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1915","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00063030-200519030-00005","article-title":"Anakinra","volume":"19","author":"Waugh","year":"2005","journal-title":"BioDrugs."},{"key":"10.1016\/j.cyto.2021.155593_b1920","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00296-011-2249-4","article-title":"Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)","volume":"32","author":"Hedrich","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cyto.2021.155593_b1925","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1930","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","article-title":"Anakinra for the treatment of rheumatoid arthritis: a safety evaluation","volume":"17","author":"Ram\u00edrez","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.cyto.2021.155593_b1935","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1940","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/acr2.11140","article-title":"Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019","volume":"2","author":"Wampler Muskardin","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.cyto.2021.155593_b1945","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/annrheumdis-2020-217706","article-title":"Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series","volume":"79","author":"Aouba","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1950","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijid.2020.11.149","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study","volume":"103","author":"Balkhair","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cyto.2021.155593_b1955","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s13054-020-03364-w","article-title":"Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study","volume":"24","author":"Kooistra","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.cyto.2021.155593_b1960","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2014.927759","article-title":"Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis","volume":"21","author":"Gon\u00e7alves","year":"2014","journal-title":"Amyloid."},{"key":"10.1016\/j.cyto.2021.155593_b1965","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00782","article-title":"Inhibition of the NOD-like receptor protein 3 inflammasome is protective in juvenile influenza a virus infection","volume":"8","author":"Coates","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1970","doi-asserted-by":"crossref","first-page":"154772","DOI":"10.1016\/j.cyto.2019.154772","article-title":"IL-1RA is part of the inflammasome-regulated immune response in bladder epithelial cells and influences colonization of uropathogenic E. coli","volume":"123","author":"Lindblad","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2021.155593_b1975","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cyto.2021.155593_b1980","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.molimm.2011.08.020","article-title":"Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis","volume":"49","author":"Niu","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cyto.2021.155593_b1985","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2021.155593_b1990","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12933-014-0158-z","article-title":"The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats","volume":"13","author":"Vallejo","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.cyto.2021.155593_b1995","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000453002","article-title":"Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation","volume":"93","author":"Frantzeskaki","year":"2017","journal-title":"Respiration."},{"key":"10.1016\/j.cyto.2021.155593_b2000","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2020-216243","article-title":"COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms","author":"Loo","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.cyto.2021.155593_b2005","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report","author":"Horby","year":"2020","journal-title":"medRxiv."},{"key":"10.1016\/j.cyto.2021.155593_b2010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jama.2020.13372","article-title":"Thrombosis in hospitalized patients with COVID-19 in a New York City health system","volume":"324","author":"Bilaloglu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cyto.2021.155593_b2015","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.chest.2020.11.005","article-title":"Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019","volume":"159","author":"Jim\u00e9nez","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.cyto.2021.155593_b2020","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study","volume":"372","author":"Rentsch","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cyto.2021.155593_b2025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19","volume":"76","author":"Paranjpe","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cyto.2021.155593_b2030","doi-asserted-by":"crossref","DOI":"10.7326\/M20-6739","article-title":"Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically Ill patients with COVID-19","author":"Al-Samkari","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cyto.2021.155593_b2035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)","volume":"196","author":"Lemos","year":"2020","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cyto.2021.155593_b2040","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"Investigators","year":"2021","journal-title":"JAMA"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466621001769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466621001769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:03:28Z","timestamp":1760907808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466621001769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":408,"alternative-id":["S1043466621001769"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2021.155593","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2021.155593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155593"}}